|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou L, Zhang R, Zhang L, Yao W, Li J and
Yuan Y: Angiotensin-converting enzyme 2 acts as a potential
molecular target for pancreatic cancer therapy. Cancer Lett.
307:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pickel L, Matsuzuka T, Doi C, Ayuzawa R,
Maurya DK, Xie S-X, Berkland C and Tamura M: Overexpression of
angiotensin II type 2 receptor gene induces cell death in lung
adenocarcinoma cells. Cancer Biol Ther. 9:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
George AJ, Thomas WG and Hannan RD: The
renin-angiotensin system and cancer: old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010.PubMed/NCBI
|
|
6
|
Wilop S, von Hobe S, Crysandt M, Esser A,
Osieka R and Jost E: Impact of angiotensin I converting enzyme
inhibitors and angiotensin II type 1 receptor blockers on survival
in patients with advanced non-small-cell lung cancer undergoing
first-line platinum-based chemotherapy. J Cancer Res Clin Oncol.
135:1429–1435. 2009. View Article : Google Scholar
|
|
7
|
Li H, Qi Y, Li C, Braseth LN, Gao Y,
Shabashvili AE, Katovich MJ and Sumners C: Angiotensin type 2
receptor-mediated apoptosis of human prostate cancer cells. Mol
Cancer Ther. 8:3255–3265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Redondo-Müller MA, Stevanovic-Walker M,
Barker S, Puddefoot JR and Vinson GP: Anti-cancer actions of a
recombinant antibody (R6313/G2) against the angiotensin II AT1
receptor. Endocr Relat Cancer. 15:277–288. 2008.PubMed/NCBI
|
|
9
|
Nakai Y, Isayama H, Ijichi H, Sasaki T,
Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y,
et al: Inhibition of renin-angiotensin system affects prognosis of
advanced pancreatic cancer receiving gemcitabine. Br J Cancer.
103:1644–1648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng Y, Ni L, Wan H, Fan L, Fei X, Ma Q,
Gao B, Xiang Y, Che J and Li Q: Overexpression of ACE2 produces
antitumor effects via inhibition of angiogenesis and tumor cell
invasion in vivo and in vitro. Oncol Rep.
26:1157–1164. 2011.PubMed/NCBI
|
|
11
|
Okamoto K, Tajima H, Nakanuma S, Sakai S,
Makino I, Kinoshita J, Hayashi H, Nakamura K, Oyama K, Nakagawara
H, et al: Angiotensin II enhances epithelial-to-mesenchymal
transition through the interaction between activated hepatic
stellate cells and the stromal cell-derived factor-1/CXCR4 axis in
intrahepatic cholangiocarcinoma. Int J Oncol. 41:573–582. 2012.
|
|
12
|
Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han
B, Xiang Y, Che J, Cao H, Fei X, et al: The angiotensin-converting
enzyme 2 in tumor growth and tumor-associated angiogenesis in
non-small cell lung cancer. Oncol Rep. 23:941–948. 2010.PubMed/NCBI
|
|
13
|
Ni L, Feng Y, Wan H, Ma Q, Fan L, Qian Y,
Li Q, Xiang Y and Gao B: Angiotensin-(1–7) inhibits the migration
and invasion of A549 human lung adenocarcinoma cells through
inactivation of the PI3K/Akt and MAPK signaling pathways. Oncol
Rep. 27:783–790. 2012.
|
|
14
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puddefoot JR, Udeozo UK, Barker S and
Vinson GP: The role of angiotensin II in the regulation of breast
cancer cell adhesion and invasion. Endocr Relat Cancer. 13:895–903.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uemura H, Ishiguro H, Nagashima Y, Sasaki
T, Nakaigawa N, Hasumi H, Kato S and Kubota Y: Antiproliferative
activity of angiotensin II receptor blocker through cross-talk
between stromal and epithelial prostate cancer cells. Mol Cancer
Ther. 4:1699–1709. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanehira T, Tani T, Takagi T, Nakano Y,
Howard EF and Tamura M: Angiotensin II type 2 receptor gene
deficiency attenuates susceptibility to tobacco-specific
nitrosamine-induced lung tumorigenesis: involvement of transforming
growth factor-beta-dependent cell growth attenuation. Cancer Res.
65:7660–7665. 2005.
|
|
18
|
Tikellis C, Bernardi S and Burns WC:
Angiotensin-converting enzyme 2 is a key modulator of the
renin-angiotensin system in cardiovascular and renal disease. Curr
Opin Nephrol Hypertens. 20:62–68. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bangalore S, Kumar S, Kjeldsen SE, Makani
H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C and
Messerli FH: Antihypertensive drugs and risk of cancer: network
meta-analyses and trial sequential analyses of 324,168 participants
from randomised trials. Lancet Oncol. 12:65–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pasternak B, Svanström H, Callréus T,
Melbye M and Hviid A: Use of angiotensin receptor blockers and the
risk of cancer. Circulation. 123:1729–1736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang CH, Lin JW, Wu LC and Lai MS:
Angiotensin receptor blockade and risk of cancer in type 2 diabetes
mellitus: a nationwide case-control study. J Clin Oncol.
29:3001–3007. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bhaskaran K, Douglas I, Evans S, van Staa
T and Smeeth L: Angiotensin receptor blockers and risk of cancer:
cohort study among people receiving antihypertensive drugs in UK
General Practice Research Database. BMJ. 344:e26972012. View Article : Google Scholar
|
|
23
|
Ferrario CM: ACE2: more of Ang-(1–7) or
less Ang II? Curr Opin Nephrol Hypertens. 20:1–6. 2011.
|
|
24
|
Gembardt F, Sterner-Kock A, Imboden H,
Spalteholz M, Reibitz F, Schultheiss HP, Siems WE and Walther T:
Organ-specific distribution of ACE2 mRNA and correlating peptidase
activity in rodents. Peptides. 26:1270–1277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva
RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N,
Pourang D, et al: The angiotensin-converting enzyme
2/angiogenesis-(1–7)/Mas axis confers cardiopulmonary protection
against lung fibrosis and pulmonary hypertension. Am J Respir Crit
Care Med. 182:1065–1072. 2010.
|
|
26
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moustakas A and Heldin CH: Induction of
epithelial-mesenchymal transition by transforming growth factor β.
Semin Cancer Biol. 22:446–454. 2012.
|
|
28
|
Perez RE, Navarro A, Rezaiekhaligh MH,
Mabry SM and Ekekezie II: TRIP-1 regulates TGF-β1-induced
epithelial-mesenchymal transition of human lung epithelial cell
line A549. Am J Physiol Lung Cell Mol Physiol. 300:L799–L807.
2011.PubMed/NCBI
|
|
29
|
Arnold SA, Rivera LB, Carbon JG, Toombs
JE, Chang CL, Bradshaw AD and Brekken RA: Losartan slows pancreatic
tumor progression and extends survival of SPARC-null mice by
abrogating aberrant TGFβ activation. PLoS One.
7:e313842012.PubMed/NCBI
|
|
30
|
Burns WC, Velkoska E, Dean R, Burrell LM
and Thomas MC: Angiotensin II mediates epithelial-to-mesenchymal
transformation in tubular cells by ANG 1-7/MAS-1-dependent
pathways. Am J Physiol Renal Physiol. 299:F585–F593. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rodrigues-Ferreira S, Abdelkarim M,
Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, Pontes
CL, Molina A, Cagnard N, Letourneur F, et al: Angiotensin II
facilitates breast cancer cell migration and metastasis. PLoS One.
7:e356672012. View Article : Google Scholar : PubMed/NCBI
|
